Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15480644 | 0.84 | HDAC6 (0.44) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL15480581 | 0.82 | HDAC6 (0.54) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL15480631 | 0.77 | HPGD (0.47) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL15480640 | 0.77 | HDAC6 (0.45) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL15482236 | 0.76 | MAPT (0.57) | HPGDALDH1A1SIRT2 | |
| SCHEMBL15482244 | 0.74 | HPGD (0.69) | KMT2AMEN1HPGDALDH1A1 | |
| SCHEMBL23054939 | 0.74 | SIRT2 (0.43) | HDAC6HDAC1HDAC8L3MBTL1HPGD | |
| SCHEMBL15480595 | 0.74 | KDM4E (0.48) | HPGDALDH1A1SIRT2 | |
| SCHEMBL15480625 | 0.74 | GPR55 (0.59) | HDAC6KMT2AMEN1HPGDALDH1A1 | |
| SCHEMBL15480643 | 0.73 | ALDH1A1 (0.61) | HDAC6HDAC1HDAC8HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB (SE) | 2021-03-04 | — | — | US | disclosed |
| US-20170333398-A1 | HETEROCYCLIC DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-11-23 | — | — | US | disclosed |
| EP-3214076-A1 | HETEROCYCLIC DERIVATIVE HAVING AMPK ACTIVATING EFFECT | Shionogi & Co., Ltd. (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2017-01-26 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC6 10/4885HDAC1 2/4885HDAC8 4/4885 |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC6 10/4885HDAC1 2/4885HDAC8 4/4885 |
| US-20170333398-A1 | HETEROCYCLIC DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | PRKAR2B, PRKAR2A, PRKAG3 | HDAC6 1504/4885HDAC1 1419/4885HDAC8 118/4885 |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC6 10/4885HDAC1 2/4885HDAC8 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.